The natural progression of Gambiense sleeping sickness: what is the evidence?

The natural progression of Gambiense sleeping sickness: what is the evidence?

Gambiense human African trypanosomiasis (HAT, sleeping sickness) is widely assumed to be 100% pathogenic and fatal. However, reports to the contrary exist, and human trypano-tolerance has been postulated. Furthermore, there is uncertainty about the actual duration of both stage 1 and stage 2 infecti...

Full description

Bibliographic Details
Main Authors:	Francesco Checchi, João A N Filipe, Michael P Barrett, Daniel Chandramohan
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2008-01-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC2602732?pdf=render

Similar Items

Estimates of the duration of the early and late stage of gambiense sleeping sickness
by: Chandramohan Daniel, et al.
Published: (2008-02-01)

Gambiense sleeping sickness: re-emerging and soon untreatable?
by: Simon Van Nieuwenhove

Gambiense sleeping sickness: re-emerging and soon untreatable?
by: Simon Van Nieuwenhove
Published: (2000-11-01)

Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis.
by: Francesco Checchi, et al.
Published: (2011-07-01)

Assessing strategies against gambiense sleeping sickness through mathematical modeling
by: Rock, K, et al.
Published: (2018)

Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness.
by: Dieudonné Mumba Ngoyi, et al.
Published: (2014-06-01)

Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa.
by: Vincent Jamonneau, et al.
Published: (2015-02-01)

Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo
by: Ching-I Huang, et al.
Published: (2022-03-01)

Specificity of malaria rapid diagnostic tests is affected by <it>Trypanosoma brucei gambiense</it> sleeping sickness
by: Gillet Philippe, et al.
Published: (2012-10-01)

Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan
by: Checchi Francesco, et al.
Published: (2012-08-01)

Domestic animals as potential reservoir hosts of Trypanosoma brucei gambiense in sleeping sickness foci in Cameroon
by: Njiokou F., et al.
Published: (2010-03-01)

NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
by: Oliver Yun, et al.
Published: (2010-05-01)

In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
by: Caecilia Schmid, et al.
Published: (2012-01-01)

Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.
by: Patient Pati Pyana, et al.
Published: (2011-01-01)

Costs of using "tiny targets" to control Glossina fuscipes fuscipes, a vector of gambiense sleeping sickness in Arua District of Uganda.
by: Alexandra P M Shaw, et al.
Published: (2015-03-01)

Comparison of stochastic and deterministic models for gambiense sleeping sickness at different spatial scales: A health area analysis in the DRC.
by: Christopher N Davis, et al.
Published: (2024-04-01)

Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug
by: Swiss Medical Weekly
Published: (2002-02-01)

Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.
by: Natalia Tiberti, et al.
Published: (2013-01-01)

Molecular identification of Trypanosoma brucei gambiense in naturally infected pigs, dogs and small ruminants confirms domestic animals as potential reservoirs for sleeping sickness in Chad
by: Vourchakbé Joël, et al.
Published: (2020-01-01)

Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
by: Patient Pyana Pati, et al.
Published: (2014-10-01)

Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.
by: Stijn Deborggraeve, et al.
Published: (2011-02-01)

Comparative analysis of cerebrospinal fluid from the meningo-encephalitic stage of T. b. gambiense and rhodesiense sleeping sickness patients using TMT quantitative proteomics
by: Natalia Tiberti, et al.
Published: (2015-09-01)

A mathematical model for evaluating the role of trypanocide treatment of cattle in the epidemiology and control of Trypanosoma brucei rhodesiense and T. b. gambiense sleeping sickness in Uganda
by: Julianne Meisner, et al.
Published: (2019-05-01)

Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.
by: Pere P Simarro, et al.
Published: (2015-01-01)

Syndromic algorithms for detection of gambiense human African trypanosomiasis in South Sudan.
by: Jennifer J Palmer, et al.
Published: (2013-01-01)

Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
by: Andrea Kuemmerle, et al.
Published: (2020-01-01)

Identifying transmission cycles at the human-animal interface: the role of animal reservoirs in maintaining gambiense human african trypanosomiasis.
by: Sebastian Funk, et al.
Published: (2013-01-01)

Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study
by: Dr. Philippe Büscher, PhD, et al.
Published: (2014-06-01)

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study
by: Andrea Kuemmerle, et al.
Published: (2021-11-01)

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
by: Andrea Kuemmerle, et al.
Published: (2021-11-01)

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
by: Francesco Checchi, et al.
Published: (2007-11-01)

Identification of Trypanosoma brucei gambiense in naturally infected dogs in Nigeria
by: Paschal Ugochukwu Umeakuana, et al.
Published: (2019-08-01)

African Trypanosomiasis Gambiense, Italy
by: Zeno Bisoffi, et al.
Published: (2005-11-01)

The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis.
by: Michael P Barrett
Published: (2018-12-01)

Sleeping Sickness at the Crossroads
by: Christian Burri
Published: (2020-04-01)

Changing landscapes, changing practice: negotiating access to sleeping sickness services in a post-conflict society
by: Palmer, JJ, et al.
Published: (2014)

Neural Damage in Experimental Trypanosoma brucei gambiense Infection: Hypothalamic Peptidergic Sleep and Wake-Regulatory Neurons
by: Claudia Laperchia, et al.
Published: (2018-02-01)

The young, the weak and the sick: evidence of natural selection by predation.
by: Meritxell Genovart, et al.
Published: (2010-03-01)

A mixed methods study of a health worker training intervention to increase syndromic referral for gambiense human African trypanosomiasis in South Sudan.
by: Jennifer J Palmer, et al.
Published: (2014-03-01)

Late stage infection in sleeping sickness.
by: Hartwig Wolburg, et al.
Published: (2012-01-01)